Raltitrexed–eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer

Limited information on salvage treatment in patients affected by pancreatic cancer is available. At failure, about half of the patients present good performance status (PS) and are candidate for further treatment. Patients >18 years, PS ⩾50, with metastatic pancreatic adenocarcinoma previously tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Reni, M, Pasetto, L, Aprile, G, Cordio, S, Bonetto, E, Dell'oro, S, Passoni, P, Piemonti, L, Fugazza, C, Luppi, G, Milandri, C, Nicoletti, R, Zerbi, A, Balzano, G, Di Carlo, V, Brandes, A A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361378/
https://www.ncbi.nlm.nih.gov/pubmed/16508631
http://dx.doi.org/10.1038/sj.bjc.6603026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361378/
https://www.ncbi.nlm.nih.gov/pubmed/16508631
http://dx.doi.org/10.1038/sj.bjc.6603026

Ejemplares similares